Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Benitec Biopharma (BNTC) Non Operating Investment Income (2019 - 2023)

Historic Non Operating Investment Income for Benitec Biopharma (BNTC) over the last 5 years, with Q4 2023 value amounting to -$1000.0.

  • Benitec Biopharma's Non Operating Investment Income rose 6666.67% to -$1000.0 in Q4 2023 from the same period last year, while for Dec 2024 it was -$1000.0, marking a year-over-year increase of 7500.0%. This contributed to the annual value of -$1000.0 for FY2024, which is 6666.67% up from last year.
  • Benitec Biopharma's Non Operating Investment Income amounted to -$1000.0 in Q4 2023, which was up 6666.67% from $1000.0 recorded in Q2 2023.
  • Benitec Biopharma's Non Operating Investment Income's 5-year high stood at $19000.0 during Q2 2021, with a 5-year trough of -$23000.0 in Q4 2021.
  • Moreover, its 5-year median value for Non Operating Investment Income was -$1000.0 (2019), whereas its average is $71.43.
  • Its Non Operating Investment Income has fluctuated over the past 5 years, first plummeted by 220000.0% in 2021, then skyrocketed by 20000.0% in 2023.
  • Quarter analysis of 5 years shows Benitec Biopharma's Non Operating Investment Income stood at -$1000.0 in 2019, then changed by 0.0% to -$1000.0 in 2020, then tumbled by 2200.0% to -$23000.0 in 2021, then soared by 86.96% to -$3000.0 in 2022, then skyrocketed by 66.67% to -$1000.0 in 2023.
  • Its Non Operating Investment Income was -$1000.0 in Q4 2023, compared to $1000.0 in Q2 2023 and -$4000.0 in Q1 2023.